Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.

MP, Morrow; KA, Kraynyak; AJ, Sylvester; X, Shen; D, Amante; L, Sakata; L, Parker; J, Yan; J, Boyer; C, Roh; L, Humeau; AS, Khan; K, Broderick; K, Marcozzi-Pierce; M, Giffear; J, Lee; CL, Trimble; JJ, Kim; NY, Sardesai; DB, Weiner; ML, Bagarazzi

doi:10.1038/mto.2016.25

Public

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100.

Shared by NobleBlocks on Nov 30, 2016 • 12:00 AM UTC

Authors:

Morrow MP

Kraynyak KA

Sylvester AJ

Abstract

We have previously demonstrated the immunogenicity of VGX-3100, a multicomponent DNA immunotherapy for the treatment of Human Papillomavirus (HPV)16/18-positive CIN2/3 in a phase 1 clinical trial. Here, we report on the ability to boost immune responses with an additional dose of VGX-3100. Patients ...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!